TENTATIVE AGENDA

10:00 - 10:05 Welcome, Announcements and Introductions         Chairman
10:05 - 10:15 Minutes Review                                       Discussion/Approval
10:15 - 10:25 Pharmacy Program/ Budget Update - Steve Calloway/Christine Thompson
10:25 - 10:35 DUR Update                                          Steve Calloway

Old Business
10:35 – 10:45 A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA’s)   Steve Calloway

New Business
10:45 – 11:30 B. Proposed Actions - New Drug/Product Review (See website and Attached Summary)   Steve Calloway

i. Open Access
   ii. Clinical Edit/Step Therapy
   iii. PDL Products
   iv. Prior Authorization
       • Discussion
       • Public Hearing
       • Decision

11:30 – 11:45 C. Clinical Edits

   I. Short-Acting Narcotics Clinical Edit
       • Discussion
       • Public Hearing
       • Decision

   II. Short-Acting Combination Narcotics Clinical Edit
       • Discussion
       • Public Hearing
       • Decision

   III. Opiate Reversal Agents Clinical Edit
       • Discussion
       • Public Hearing
       • Decision
D. Preferred Drug List (PDL)

I. ACE Inhibitor Agents
   - Discussion
   - Public Hearing
   - Decision

II. ACE Inhibitors/Calcium Channel Blocker Combination Agents
   - Discussion
   - Public Hearing
   - Decision

III. ACE Inhibitors/Diuretic Combination Agents
   - Discussion
   - Public Hearing
   - Decision

IV. Angiotensin Receptor Blocker Agents (ARB’s)
   - Discussion
   - Public Hearing
   - Decision

V. Angiotensin Receptor Blocker/Diuretic Combination Agents
   - Discussion
   - Public Hearing
   - Decision

VI. Angiotensin Receptor/Calcium Channel Blocker Combination Agents
   - Discussion
   - Public Hearing
   - Decision

VII. Anticoagulant Agents: Oral and Subcutaneous
   - Discussion
   - Public Hearing
   - Decision

VIII. Antiplatelet Agents
   - Discussion
   - Public Hearing
   - Decision

IX. Beta Adrenergic Blockers and Diuretic Combination Agents
   - Discussion
   - Public Hearing
   - Decision

X. Calcium Channel Blocker Agents (Dihydropyridines)
   - Discussion
   - Public Hearing
   - Decision
XI. Calcium Channel Blocker Agents (Non-Dihydropyridines)
- Discussion
- Public Hearing
- Decision

XII. Direct Renin Inhibitors and Combination Agents
- Discussion
- Public Hearing
- Decision

XIII. Hepatitis C Therapy: Direct-Acting Antiviral Agents
- Discussion
- Public Hearing
- Decision

XIV. Homozygous Familial Hypercholesterolemia Products
- Discussion
- Public Hearing
- Decision

XV. Lipotropic Agents: Niacin and Combination Preparations
- Discussion
- Public Hearing
- Decision

XVI. Lipotropic Agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products
- Discussion
- Public Hearing
- Decision

XVII. Proton Pump Inhibitor Agents
- Discussion
- Public Hearing
- Decision

XVIII. Pulmonary Hypertension Agents: Inhaled/Injectable
- Discussion
- Public Hearing
- Decision

XIX. Pulmonary Hypertension Agents: Oral
- Discussion
- Public Hearing
- Decision

XX. Sympatholytic Antihypertensive Agents
- Discussion
- Public Hearing
- Decision
XXI. Triglyceride Lowering Agents
   • Discussion
   • Public Hearing
   • Decision

E. Preferred Drug List Classes for Dec/Jan
   i. Process Discussion
   ii. Therapeutic classes/to be announced at meeting

1:00 LUNCH
1:15-1:30 Program Utilization Information-Xerox Update Luke Boehmer
1:30-1:50 Other Business
   • “Top 25” Drugs by Cost/Claims
   • Clinical Edit Summary Report
   • Call Center Statistics

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: December 15, 2016
Department of Natural Resources - 1101 Riverside Dr.
Lacharrette/Nightengale Rooms